KRAS and colorectal carcinoma: The combination of β-elemene and cetuximab can induce ferroptosis and inhibit the migration of CRC cells mutated in KRAS by inducing ROS accumulation, consuming GSH, lipid peroxidation, upregulating HO-1 and transferrin, downregulating GPX4, SLC7A11, FTH1 and SLC40A1.474 The above effects were eliminated after the use of ferroptosis inhibitor.474 By inducing ferroptosis, it is expected to provide a prospective strategy for CRC patients with KRAS mutation.